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Summary
 
Molecular mimicry refers to structural homologies between a self-protein and a microbial protein.
A major epitope of myelin basic protein (MBP), p87–99 (VHFFKNIVTPRTP), induces experi-
mental autoimmune encephalomyelitis (EAE). VHFFK contains the major residues for binding of
this self-molecule to T cell receptor (TCR) and to the major histocompatibility complex. Pep-
tides from papilloma virus strains containing the motif VHFFK induce EAE. A peptide from hu-
man papilloma virus type 40 (HPV 40) containing VHFFR, and one from HPV 32 containing
VHFFH, prevented EAE. A sequence from 
 
Bacillus subtilis
 
 (RKVVTDFFKNIPQRI) also pre-
vented EAE. T cell lines, producing IL-4 and specific for these microbial peptides, suppressed EAE.
Thus, microbial peptides, differing from the core motif of the self-antigen, MBPp87–99, function
 
as altered peptide ligands, and behave as TCR antagonists, in the modulation of autoimmune disease.
Key words: experimental autoimmune encephalomyelitis • mimicry • altered peptide ligand • 
autoimmunity • multiple sclerosis
 
W
 
hen certain neurotropic viruses trigger inflammation
in the central nervous system (CNS),
 
1
 
 immune cells
in the inflammatory infiltrate attack neighboring myelin
antigens in the CNS. This immune response then spreads
to various epitopes on various myelin antigens, a process
known as epitope spreading (2–4). Certain altered peptide
ligands (APLs) actually resemble the immunogenic portion
of certain neurotropic viruses, and can be used to subvert
epitope spreading. Indeed, we have been able to suppress
the spreading response by administering various APLs that
mimic the structure of both certain microbes and a compo-
nent of myelin. These APLs induce IL-4 and either prevent
or reverse experimental autoimmune encephalomyelitis
(EAE). Administration of such APLs may clear an entire in-
flammatory infiltrate that contains a diverse collection of T
cells and B cells from the brain (2, 3, 5–7).
In the (PLSJL/J)F1 mouse there are numerous pathogenic
epitopes of myelin antigens that induce EAE. These include
several on myelin basic protein (MBP): pAc1–11, restricted
by I-A
 
u
 
; p35–47, restricted by I-E
 
u
 
; and p87–99, restricted
by I-A
 
s
 
 (8–13). Moreover, the immune response to other
epitopes in MBP is actually restricted by hybrid determinants
where the 
 
a 
 
chain is encoded by I-A
 
s
 
, and the 
 
b 
 
chain by I-A
 
u
 
(8). In the (PLSJL/J)F1, the dominant immunogenic and
pathogenic epitope of MBP is pAc1–11. MBPp87–99 is re-
stricted by I-A
 
s
 
 and is a minor determinant (9, 10). Further-
more, after immunization of SJL mice with spinal cord ho-
mogenate, other myelin antigens such as proteolipid protein
(PLP) are actually more pathogenic than MBP (14, 15).
MBPp87–99 is an immunodominant epitope for T cells
and autoantibodies in MS brain lesions (16–19). The main re-
gion of MBP recognized by T cells and autoantibodies, found
in MS brain, is the core motif, HFFK, from MBPp87–99 in
patients who are HLA-DRB1*1501 DQB1*0602 (HLA-
DR2). Recently, Smith et al. solved the crystal structure of
HLA-DR2 with MBPp84–102, and confirmed that K91 is
the major TCR contact site, while F90 is a major anchor to
MHC, binding the hydrophobic P4 pocket (20).
 
1
 
Abbreviations used in this paper:
 
 APL, altered peptide ligand; CNS, central ner-
vous system; EAE, experimental autoimmune encephalomyelitis; gpSCH,
guinea pig spinal cord homogenate; HPV, human papilloma virus; HSV, her-
pes simplex virus; HVS, herpes virus 
 
Saimiri
 
; MBP, myelin basic protein;
MOG, myelin oligodendroglial glycoprotein; MS, multiple sclerosis. 
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Previously, we have compared the structural require-
ments for autoantibody recognition to those of T cell clones
reactive to MBPp87–99. MBP autoantibodies were affin-
ity-purified from CNS lesions of 12 postmortem cases
studied. The MBPp87–99 peptide was immunodominant
in all cases and it inhibited autoantibody binding to MBP
by 
 
.
 
95%. Residues contributing to autoantibody binding
were located in a 10-amino acid segment p86–95 (VVH-
FFKNIVT) that also contained the MHC–TCR residues
for T cells recognizing MBP in the context of DRB1*1501
and DQB1*0602. In the epitope center, the same residues,
VHFFK, were important for T cell binding and MHC rec-
ognition. Based on the antibody binding motif, microbial
peptides that were bound by purified autoantibodies were
identified. Autoantibody binding of microbial peptides re-
quired sequence identity at four or five contiguous residues
in the epitope center VHFFK. Papilloma viruses (types 7,
13, 40, and 32), EBV, cytomegalovirus, Dhori virus, herpes
simplex virus (HSV) type 1, influenza type A, hepatitis A,
and adenovirus were efficient at binding autoantibodies to
MBP. All these viruses contained the FFK or FFKN motifs.
The papilloma virus type 7 (IGGRVHFFKDISPIA) bound
both autoantibodies to MBP found in brain, and it stimu-
lated a human MBP-specific T cell clone from an MS pa-
tient (19, 21).
In this report we have chosen microbial peptides that
bear chemical similarities with MBPp87–99 and demonstrate
how these epitopes derived from microbial sequences, can
function like an APL, and suppress EAE. In a companion
paper, sequences bearing the motif HFFK derived from
various microbes including human papilloma virus type 7
(HPV 7) induced EAE after administration in CFA, or after
in vitro stimulation of an MBP-specific T cell clone (1).
 
Materials and Methods
 
Animals.
 
6–8-wk-old female (PLSJL/J)F1 mice were purchased
from The Jackson Laboratory.
 
Antigens.
 
Peptides were synthesized on a peptide synthesizer
(model 9050: MilliGen) by standard 9-fluorenylmethoxycarbonyl
chemistry. Peptides were purified by HPLC. Structure was
confirmed by amino acid analysis and mass spectroscopy. Peptides
used for the experiments were: ENPVVHFFKNIVTPR (MBP
p85–99); AASQKRPSQRHG (MBPAc1–11); IGGRVHFFKDIS-
PIA (HPV 7); IGGRVHFFKDISPIS (HPV 13); IGGRVHF-
FRDISPIG (HPV 40); IGSRVHFFHDISPIT (HPV 32); RKV-
VTDFFKNIPQRI (
 
Bacillus subtilis
 
 hyp protein X13); and
DMTPADALDDRDLEM (HSV VP16).
 
Peptide Treatment.
 
For the peptide treatment a solution of
2 mg/ml of peptide dissolved in PBS, emulsified 1:1 (vol/vol) in
IFA was prepared. Mice were injected intradermally with 0.1 ml
of the antigen emulsion, twice with a 10-d interval. 10 d after the
last injection experimental animals were challenged for EAE.
 
EAE Induction.
 
Lyophilized guinea pig spinal cord (gpSCH)
was dissolved in PBS to a concentration of 5 mg/ml and emulsi-
fied with an equal volume of IFA, supplemented with 4 mg/ml
heat-killed 
 
Mycobacterium tuberculosis
 
 H37Ra (Difco Labs.). Mice
were injected subcutaneously with 0.1 ml of the peptide emul-
sion, and again on the same day and then 48 h later were injected
 
intravenously with 0.1 ml of a solution of 4 
 
m
 
g/ml 
 
Bordetella per-
tussis
 
 toxin in PBS. Experimental animals were scored as follows:
0, no clinical disease; 1, tail weakness or paralysis; 2, hind limb
weakness; 3, hind limb paralysis; 4, forelimb weakness or paraly-
sis; 5, moribund or dead.
 
T Cell Lines.
 
Lymph node cells from experimental animals
were taken 20 d after challenge for EAE. Cells (5–10 
 
3 
 
10
 
6
 
/ml)
were incubated in enriched RPMI (RPMI 1640 supplemented
with 
 
l
 
-glutamine [2 mM], sodium pyruvate [1 mM], nonessential
amino acids [0.1 mM], penicillin [100 U/ml], streptomycin
[0.1mg/ml], and 2-ME [5 
 
3 
 
10
 
2
 
5
 
 M]), supplemented with 1%
syngeneic mouse sera with 10 
 
m
 
g/ml peptide for 3 d. After incu-
bation, cells were washed and resuspended for 10 d in enriched
RPMI completed with 10% FCS and 10% supernatant of spleen
cells activated with concanavalin A (Con A sup). After this period
of culture the cells were then activated in the presence of synge-
neic irradiated spleen cells (10
 
7
 
/ml) and 10 
 
m
 
g/ml peptide for
3 d, washed and incubated for 10 d in enriched RPMI comple-
mented with 10% FCS and 10% Con A sup. The cells were con-
tinuously grown in the above conditions for 2-wk cycles. The
peptide-specific T cells were used for assays 1 wk after antigen
stimulation.
 
T Cell Line Proliferation Assay.
 
T cells (10
 
4
 
) were incubated in
96-well flat-bottomed plates (Corning) with 5 
 
3 
 
10
 
5 
 
irradiated
syngeneic APC in a total volume of 200 
 
m
 
l of enriched RPMI
and 10% FCS, and different concentrations of the peptide. After
24 h 100 
 
m
 
l were removed from each well for cytokine secretion
analysis in a sandwich ELISA. The remaining cells were incu-
bated for an additional 24 h, pulsed with [
 
3
 
H]thymidine (0.5 
 
m
 
Ci
of 5 Ci/mmol), harvested, and counted in a beta counter.
 
Class II Peptide Binding Assay.
 
Peptide binding assays were
performed as described elsewhere (22). In brief, the B cell lym-
phoma LS102.9 was used as a source of I-A
 
s
 
. The cell line was
maintained in vitro by culture in enriched RPMI. Cells were lysed
at a concentration of 10
 
8 
 
cells/ml in PBS containing 1% NP-40,
1 mM PMSF, 5 mM Na-orthovanadate, and 25 mM iodoaceta-
mide. The lysates were cleared of debris and nuclei by centrifuga-
tion at 10,000 
 
g 
 
for 20 min.
Mouse class II
 
 
 
molecules were purified as previously described
(22) using the mAb Y3JP (IA
 
b,s 
 
-specific), coupled to Sepharose 4B
beads. Purified mouse class II molecules (5–500 nM) were incu-
bated with 1–10 nM 
 
125
 
I-radiolabeled peptides for 48 h in PBS con-
taining 5% DMSO in the presence of a protease inhibitor cocktail.
Purified peptides were iodinated using the chloramine-T method.
Peptide inhibitors were typically tested at concentrations rang-
ing from 120 
 
m
 
g/ml to 1.2 ng/ml. The data were then plotted
and the dose yielding 50% inhibition (IC
 
50
 
) was measured. Inter-
mediate binding was equivalent to IC
 
50
 
 in the range of 100–1,000
nM. In appropriate stoichiometric conditions, the IC
 
50
 
 of an un-
labeled test peptide to the purified MHC is a reasonable approxi-
mation of the affinity of interaction (
 
K
 
d
 
). Peptides were tested in
two to four completely independent experiments.
Class II peptide complexes were separated from free peptide
by gel filtration on TSK2000 columns (TosoHaas 16215), and the
fraction of bound peptide calculated as previously described (22).
In preliminary experiments, each of the I-A prep was titered in
the presence of fixed amounts of radiolabeled peptides to deter-
mine the concentration of class II molecules necessary to bind
10–20% of the total radioactivity. All subsequent inhibition and
direct binding assays were then performed using these class II
concentrations.
 
TCR Antagonist Assay.
 
TCR antagonism was tested as previ-
ously described (23). In brief, irradiated syngeneic spleen cells 
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were pulsed with a 0.005 
 
m
 
M concentration of MBPp85–99 for
3 h at 37
 
8
 
C. Spleen cells were then washed and used as APCs to
the MBPp85–99 (L35) specific T cell line in the presence of dif-
ferent inhibitor concentration. Proliferative responses were mea-
sured by [
 
3
 
H]thymidine incorporation. Percentage of inhibition
was calculated by the formula described in Table III.
 
Results
 
Microbial Peptides Block EAE Induction with gpSCH in the
(PLSJL/J)F1 Mouse.
 
We asked whether microbial peptides
with structural similarities to the self-peptide MBPp85–99
would block EAE. We made slight modifications of a proto-
col used previously to prevent EAE by APLs (23). Mice
were injected intradermally twice at 10-d intervals with 0.1
mg of peptide in IFA. 10 d after the last injection the animals
were challenged with gpSCH in order to induce EAE. As
seen in Table I, the incidence, mean day of onset, and mean
peak severity were significantly lower for papilloma virus 40
(VHFFR), papilloma virus 32 (VHFFH), and 
 
Bacillus subtilis
 
open reading frame (ORF) (DFFK) than for the IFA alone
control or the MBPp85–99/IFA control (
 
P
 
 , 
 
0.001). Mice
injected with HPV 7 VHFFK, HPV 13 VHFFK, or the na-
tive peptide MBPp85–99 have an increased disease inci-
dence, compared with microbial sequences mutated at the
main or secondary TCR contact sites, 91K and 88H respec-
tively, although there was a significant delay of disease onset
and mean maximal disease score when compared with IFA
control mice (
 
P
 
 , 
 
0.01). Nevertheless, only peptides from
HPV 40 and 
 
Bacillus subtilis
 
 ORF were effective in amelio-
ration of all the clinical parameters, clinical incidence, mean
day of onset, and mean peak severity of disease, (
 
P
 
 , 
 
0.001).
Thus, viral peptides with limited homology to a self-MBP
peptide induce protection to EAE in (PLSJL/J)F1 mice. As
seen in Table I, when the motif found in MBPp85–99 is
mutated from VHFFK (found in MBP and in HPV 7) to
VHFFR in HPV 40, or VHFFH in HPV 32, these micro-
bial peptides reduce EAE induced with gpSCH from 100%
incidence (20 out of 20 with IFA alone and 31 out of 40
with MBPp85–99 or HPV 7), to 20% incidence (8 out of 40
with HPV 40 or 32) (
 
P
 
 , 
 
0.01). Thus, a mutation of the
major TCR contact site K91 abrogates EAE, a T cell–medi-
ated disease, whereas mutation of the secondary TCR binding
site at H88 in 
 
Bacillus subtilis
 
 ORF totally eliminates disease
(
 
P 
 
, 
 
0.001). Since EAE is a T cell–mediated autoimmune dis-
ease, these studies support the idea that the microbial se-
quences mutated at 91K or 88H are APLs: Paul M. Allen, the
discoverer of APLs, defines them in this way, “We subse-
quently defined the term ‘altered peptide ligand’ to de-
scribe analogues of immunogenic peptides in which the
TCR contact sites have been manipulated. While these
peptides do not stimulate T cell clonal proliferation, they
nevertheless have the capacity to activate some TCR-medi-
ated effector functions. Other peptide analogues do not
stimulate any detectable function from the T cells and are
simply termed peptide analogues” (24). Another refinement
of the definition in 1998 by Allen again states: “These pep-
tides bind to [MHC class II] with similar affinities, but have
different potencies to induce T cell functions: [two substi-
tutions] do not cause T cell proliferation at any concentra-
tion, and [one] causes minimal proliferation only at the
highest concentrations; all these peptides, however can act
as antagonists” (25). The peptides used in this study are the
same: they are APLs that do not cause proliferation of na-
tive peptide with VHFFK, but nevertheless antagonize it,
and bind with similar affinities to MHC class II (see Table
III). They significantly alter the ability of MBPp87–99
TCR to induce EAE. It is important to note that HPV 7,
containing the HFFK motif, cross-reacts with MBPp87–99.
Thus an HPV 7 peptide can stimulate MBPp87–99 T cell
lines and induce relapsing EAE. Likewise, MBPp87–99 can
cross-stimulate an HPV 7 T cell line and induce relapsing
EAE (1). If the K91 is mutated as it is in HPV 32 or 40, EAE
is prevented. This dramatic change in T cell phenotype, in-
 
Table I.
 
Clinical Parameters in (PLSJL/J)F1 Mice Immunized with Microbial Mimicry Peptides and Challenged for EAE Induction
with gpSCH
 
IFA immunization
 
*
 
EAE
challenge
Percentage of
incidence
Mean day of
disease onset
Mean peak
disease severity
IFA alone gpSCH 100 9 
 
6
 
 15
MBPp85–99 (ENPVVHFFKNIVTPR) gpSCH 95 16 
 
6
 
 2
 
‡
 
3.6 
 
6
 
 0.9
 
‡
 
HPV 7 (IGGR
 
VHFFK
 
D
 
I
 
SPIA)
 
§
 
i
 
gpSCH 60 17 
 
6
 
 2
 
‡
 
2.3 
 
6
 
 1.2
 
‡
 
HPV 13 (IGGR
 
VHFFK
 
D
 
I
 
SPIS) gpSCH 60 16 
 
6
 
 3
 
‡
 
2.3 
 
6
 
 0.4
 
‡
 
HPV 40 (IGGR
 
VHFF
 
RD
 
I
 
SPIG) gpSCH 20 21
 
¶
 
1
 
¶
 
Bacillus subtilis
 
 ORF (RKV
 
V
 
TD
 
FFKNI
 
PQRI) gpSCH 0 0
 
¶
 
0
 
¶
 
HPV 32 (IGSR
 
VHFF
 
HD
 
I
 
SPIT) gpSCH 20 13
 
¶ 3‡
*Groups of 20 animals were used for data analysis.
‡P , 0.01 by Student’s t test compared with immunization with IFA alone.
§Amino acid homologies with the peptide MBPp87–99 are in bold.
iNote that the HPV 7 sequence we use is three amino acids shorter at its NH2 terminus than that used by Ufret-Vincenty et al. (1).
¶P , 0.001 by Student’s t test compared with immunization with MBPp87–99.1278 Microbial Epitopes Act as Altered Peptide Ligands
duction of autoimmune disease versus maintenance of self-
tolerance when mutations are made at TCR contact sites, al-
low these microbial mutant peptides to be called APLs.
T Cell Lines Isolated from Mice Immunized with Mimicry Mi-
crobial Peptides Produce IL-4 and g-IFN and Do Not Cross-react
with the Native MBPp87–99. To analyze the immune re-
sponses in the protected animals, T cell lines specific for the
viral peptides were generated. After the mice recovered
from the acute phase of disease, draining lymph node cells
were isolated and restimulated in vitro with either MBP or
various viral peptides. Table II shows cytokine profiles of T
cell lines isolated from the experimental animals. T cell
lines stimulated with HPV 13 and Bacillus subtilis ORF pro-
duced both IL-4 and g-IFN, whereas the T cell line stimu-
lated with MBPp85–99 produced IL-4, but not g-IFN. T
cells stimulated with HSV VP16 peptide, used as a control,
lacking the HFFK motif (DMTPADALDDRDLEM), failed
to proliferate or produce IL-4 or g-IFN. These experiments
demonstrate that IFA is not critical in the protective effect
of these viral peptides, as the T cell lines were derived from
animals injected with CFA and antigen. It also indicates
that within these animals it is possible to select for lines that
can be stimulated by sequences from these viral peptides.
Once these lines have been selected, there is no cross-reac-
tivity between the viral peptides and MBP. However, in
draining lymph nodes from mice injected with CFA
MBPp85–99, T cell responses to MBPp85–99 can be inhib-
ited by viral peptides mutated at the main TCR contact
site 91K, but retaining the capacity to bind to MHC class
II, I-As (see Table III below).
T Cell Lines Isolated from Mice Immunized with Mimicry Mi-
crobial Peptides Protect from EAE. To study the mechanism
of disease protection by the mimicry peptides, T cells iso-
lated from the protected mice and expanded in vitro were
reinjected to naive animals and those mice were challenged
for EAE induction by gpSCH. As seen in Fig. 1, the trans-
fer of activated T cells specific for viral peptides from HPV
13 and from Bacillus subtilis ORF and with sequences simi-
lar to MBPp87–99 protects from EAE (P , 0.01 when com-
paring mean disease score to animals given the T cell line
specific for HSV VP16). A Th2 line specific for MBPp87–99
also protects from EAE (P , 0.01) (Fig. 1).
Mimicry Microbial Peptides Bind to MHC Class II I-As Mol-
ecules and Inhibit Anti-MBPp85–99 T Cell Proliferative Re-
sponses. We tested the binding of the mimicry microbial
peptides to affinity purified I-As molecules. As shown in
Table III, all the peptides tested had intermediate binding to
the class II molecules (IC50 in the 100–1,000 nM range). The
possibility that sequence similarity between microbial pep-
tides used in our experiments and the native MBPp85–99
peptide would influence antigen specific responses against
the native MBPp85–99 peptide was tested by in vitro inhibi-
tion assay. 10 d after immunization of (PLSJL/J)F1 mice
with the MBPp85–99 peptide in CFA, draining lymph
node cells were tested for the proliferative response to the
immunizing peptide alone or together in the presence of
mimicry microbial peptides as inhibitors. As observed in
Table III, at 1:1 molar ratio the HPV 7 peptide inhibited
proliferative responses 62%, HPV 40 peptide inhibits 39%,
and Herpes simplex DNA polymerase peptide inhibits
39%. Therefore, cross-reactivity is observed between the
native MBPp85–99 peptide and the mimicry microbial
Table II. Proliferative Responses and Cytokine Profile of T Cell 
Lines Specific for Microbial Mimicry Peptides
T cell line
specificity Stimulus* Proliferation IL-4‡ g-IFN‡
CPM ng/ml ng/ml
MBPp85–99 MBPp85–99 52,580 0.14 BD
MBPp85–99 HS VP16 4,691 BD BD
MBPp85–99 none 3,479 BD BD
HPV 13 HPV 13 95,834 0.16 0.295
HPV 13 MBPp85–99 12,955 BD BD
HPV 13 none 11,938 BD BD
Bacillus subtilis
ORF Bac sub ORF 8,626 0.14 0.251
Bacillus subtilis
ORF MBPp85–99 2,430 BD BD
Bacillus subtilis
ORF none 1,557 BD BD
*T cells were isolated from experimental mice after recovery from the
acute phase of disease and expanded in vitro by stimulation with the
specific peptide. Proliferative responses are shown for each line re-
sponding to an antigen concentration of 0.01 mg/ml.
‡Cytokine concentration was measured from supernatants collected af-
ter 48 h of in vitro stimulation assays of T cell lines with a peptide con-
centration of 0.01 mg/ml. Levels ,0.01 ng/ml are reported as below
detection limits (BD).
Figure 1. Prevention of EAE by passive transfer of T cell lines specific
for microbial mimicry peptides. Mice were injected intraperitoneally with
5 3 106 T cells specific for either MBPp85–99 (h), HPV 13 peptide (e),
Bacillus subtilis ORF peptide (s), or HSV VP16 peptide (n). 10 d after cell
transfer, mice were challenged for EAE by immunization with gpSCH.
Results are expressed as mean disease score in groups of five animals.1279 Ruiz et al.
peptides at the level of inhibition of proliferative responses.
Inhibition of proliferative responses may have been due to
the capacity of the microbial peptides to mimic native
MBP, and to bind to the MHC class II I-As molecules, par-
tially inhibiting presentation of the MBPp85-99 to specific
T cells.
Microbial Peptides Protect from EAE in an Epitope-specific
Manner: Lack of a Bystander Effect. To rule out a bystander
effect by the microbial mimicry peptides, we compare
the protective effect in EAE induced by either gpSCH or
MBPpAc1–11. In Fig. 2, we show that the Bacillus subtilis
peptide injected into IFA inhibits induction of EAE in-
duced by gpSCH, but does not inhibit disease induced by
MBPpAc1–11. Therefore, the regulatory effect of mimicry
peptides requires the presence of the MBPp85–99 epitope
in the EAE-inducing antigen.
HPV 40 Peptide Acts as a TCR Antagonist. We tested for
TCR antagonism using an assay by Karin et al. (23). In this
assay we inhibit the proliferative response to wild-type
MBPp85–99 by prepulsing irradiated splenic APCs with
0.005 mM of MBPp85–99, then washing and using these
APCs to stimulate an MBPp85–99–specific T cell line in
the presence of a putative antagonist. The peptide HPV 40
(containing the motif VHFFR) inhibited proliferation by
40%, whereas a control peptide lacking the HFFK motif
did not inhibit proliferation at all (Fig. 3).
Discussion
“In MS—as in other autoimmune diseases—there has
been feverish debate between those who believe that the dis-
ease is triggered by an environmental agent and those who
champion a genetic basis. But there is actually a reasonable
reconciliation of these opposing views: certain genes confer-
ring susceptibility to the disease and certain factors in the en-
vironment are both critical for the development of autoim-
munity, and this is particularly true for MS” (7).
Molecular mimicry provides a scheme whereby viral
sensitization in the blood leads to activation of T cells (26).
These enter the brain where they encounter their cognate
mimic in myelin. We have detected a number of microbes
whose amino acid sequences can activate anti-myelin T
cells from MS patients, as well as bind to anti-myelin anti-
bodies eluted from MS brain material (19, 21). Molecular
mimicry also allows for reconciliation of the genes versus
the environment debate: genomic searches for genes linked
to MS susceptibility reveal that the most important gene in
determining susceptibility to MS is HLA (28–30). HLA is
of course critical for selecting the appropriate mimic and
presenting it to the immune system. Moreover, many dif-
ferent viruses mimic various parts of the myelin sheath, so
Table III. Inhibition of Lymph Node Cell Proliferation to MBPp85–99 by Microbial Mimicry Peptides
Peptide Sequence
Relative affinity*
for I-As
Inhibition of LNC
responses‡
%
MBPp85–99 ENPVVHFFKNIVTPR 667* –
HPV 7 IGGRVHFFKDISPIA 208 62
HPV 40 IGGRVHFFRDISPIG 180 39
Herpes simplex DNA pol GGRRLFFVKAHVRE 551 39
Herpes simplex VP16 DMTPADALDDRDLEM ND 29
*Peptide binding assays on purified I-As molecules were performed as described in reference 22. Results are expressed as IC50 in nanomolars. E. coli
E7 peptide bound at an IC50 of 76 nM.
‡For inhibition of lymph node cell (LNC) proliferative responses by microbial mimicry peptides, LNCs from (PLSJL/J)F1 mice immunized with the
MBPp85–99 peptide were incubated in vitro in the presence of both the MBPp85–99 peptide and a molecular mimicry peptide at a molar ratio of
1:1 (final concentration of each peptide was 0.01 mg/ml). CPM incorporation of the LNCs incubated with MBPp85–99 at 0.01 mg/ml were 5,792
in the absence of inhibitor and CPM of LNCs incubated with medium alone was 1,010. Percentage of inhibition was calculated with the formula: %
of inhibition 5 (1 2 SI with inhibitor / SI without inhibitor) 3 100.
Figure 2. A microbial peptide with homology to MBPp85–99 inhibits
the induction of EAE by gpSCH but does not prevent disease induction
by MBP Ac1–11. Mice were immunized with the a microbial peptide
from Bacillus subtilis and challenged for disease with either gpSCH (d) or
MBPpAc1–11 (m) in CFA. Results are expressed as mean disease score in
groups of five animals.1280 Microbial Epitopes Act as Altered Peptide Ligands
inflammation in the white matter of the brain may ensue
from an immune response to a variety of microbes. Thus,
the hope of finding the virus that triggers MS may remain
elusive forever (7).
Our study shows how molecular mimics may modulate
autoimmune disease. Earlier work by Gautam et al. (31)
had demonstrated that a polyalanine peptide with only five
native MBP residues is able to induce EAE in (PLSJL/J)F1
mice. Further analysis also showed that an 11-amino acid
peptide, consisting mostly of alanines with only four native
Ac1–11 residues, was able to induce T cell hybridoma pro-
liferation. Taking an approach of introducing either d-amino
acids or unnatural amino acids in place of l-amino acids
into MBPpAc1–11 analogues, we showed that T cells rec-
ognize only a short stretch of six or seven amino acids.
More importantly, this stretch contains only four native
MBPpAc1–11 residues. We also tested T cell recognition in
vivo, using EAE as a measure of activation. We show that a
short peptide of six amino acids with a core of only five na-
tive Ac1–11 amino acids induces EAE (31, 32).
A herpes virus Saimiri (HVS) peptide, AAQRRPSRPFA,
with a limited homology to MBP1–11 peptide, ASQKRPS-
QRHG, (bold letters show homology) can stimulate a panel
of MBP1–11–specific T cell hybridomas, and more impor-
tantly cause EAE in mice. We demonstrate that this is due
to cross recognition of these two peptides by TCRs. This
HSV peptide with homology at just five amino acids with a
self-peptide can induce clinical signs and histologic evi-
dence of EAE in mice (33).
Relapsing EAE has been induced with two peptides
bearing the HFFK motif containing the primary TCR and
MHC contact for I-E in the Lewis rat, I-A in the SJL
mouse, and DRB1*1501 in humans (5, 17, 18, 23). Using
a passive transfer protocol, T cells specific for an HPV 7
peptide (IGGRVHFFKDISPIASSE) were found to in-
duce relapsing EAE. These T cells could be activated by
MBPp87–99 to induce EAE, and MBPp87–99 T cells
could also be stimulated by the HPV 7 peptide to induce
EAE. Active EAE with this papilloma peptide was also in-
duced. Another viral peptide from EBV (RAHPVY-
FFKSACPPA) could activate the papilloma virus–specific
T cells and induce EAE by passive transfer (1).
These results have practical significance for the success of
APL therapy in MS patients. The APLs now in Phase II clin-
ical trials in MS (2) have a K®A substitution at position 91
and thus, neither bind anti-MBP antibody nor trigger MBP-
specific T cells. Administration of soluble native versions of
myelin antigens may have dangerous consequences. Genain
et al. showed that EAE induced in marmosets by immuni-
zation with myelin oligodendroglial glycoprotein (MOG)
could be delayed by intraperitoneal treatment with soluble
MOG; however, treated animals developed a severe late form
of the disease (34). In these animals, MOG-specific T cell
proliferative responses were transiently suppressed, cytokine
profiles were shifted from a Th1- to a Th2-type pattern, titers
of autoantibodies to MOG were enhanced, and autoimmune
disease was exacerbated (34). This implies that provoking a
vigorous anti-myelin reaction with a native peptide could
have dangerous consequences in a clinical setting (35).
APLs work in part by altering cytokine production in T
cells that respond to self-antigens (36–40). For example, in the
Lewis rat administration of MBPp87–99 (K91®A), an APL
altered at the primary TCR contact residue K91, reversed pa-
ralysis in EAE, and reduced production of the proinflam-
matory cytokine TNF-a (23). Another APL, MBPp87–99
(96P®A), reversed paralysis in EAE and increased production
of IL-4 at the site of disease (5). The effect of this APL was re-
versed by the in vivo administration of anti–IL-4 antibody (5).
In the studies presented here, T cell lines with specificity
for viral sequences that resemble MBPp85–99, but were
not identical to MBPp85–99, produced IL-4 and g-IFN,
two cytokines known to suppress EAE (5, 41–45). Despite
the fact that systemic administration of g-IFN is protective
in EAE, g-IFN can induce MHC class II on astrocytes
(46), and allow these glial cells to present myelin antigens
to encephalitogenic T cells. Although in EAE systemic ad-
ministration of g-IFN is protective, in MS administration
of g-IFN provokes exacerbation of disease (47).
Interestingly, a T cell line specific for MBP that pro-
duced IL-4 was also able to suppress EAE (Fig. 1). Both IL-4
and g-IFN are capable of suppressing EAE. Thus, lines spe-
cific for microbial sequences like HPV 13 or Bacillus subtilis
ORF produce both IL-4 and g-IFN and suppress EAE,
whereas a T cell line specific for MBP producing IL-4 and
no g-IFN also protects. From previously published work
we know that antibody to g-IFN and antibody to IL-4
both exacerbate EAE (5, 48). Thus, the production of anti-
inflammatory cytokines like IL-4 by T cells responding to
microbes, whose sequences resemble but are not identical
to the self-epitope MBPp87–99, has potent effects on in vivo
disease. These T cell lines can inhibit EAE in (PLSJL/J)F1
animals, induced by gpSCH. This homogenate contains
Figure 3. TCR antagonism by a peptide from HPV 40. APCs
prepulsed with MBPp85–99 (0.005 mM) were used for stimulation of a T
cell line (L35) specific for the peptide MBPp85–99, in the presence of a
mimicry microbial peptide (h) or a peptide lacking the core motif of
MBPp85–99 (e). Results are expressed as percentage of inhibition of T
cell proliferative responses. Proliferation of the L35 line in the presence of
prepulsed cells was 63773.6 CPM. Proliferation of the L35 line in the
presence of APCs alone was 423 CPM.1281 Ruiz et al.
epitopes such as MBPpAc1–11, and MBPp35–47, as well
as PLP epitopes, that dominate the pathogenic response (8–
10, 13). The trans-acting effect of such T cells, producing
antiinflammatory cytokines, is thus able to shut down a di-
versity of immune responses (2).
Suppression of autoimmune disease with microbial se-
quences can also be achieved by naked DNA immunization
with minigenes encoding the core motif of MBPp85–99
(48a). Thus, microbial genomes may direct immunization
via the information encoded in the DNA itself, and this
immunization might include sensitization to altered pep-
tides of self (49, 50).
The notion that microbial sequences can act as APLs and
suppress autoimmune disease appears to be novel. Com-
bined with the observation that microbial mimics can also
induce EAE (1, 33, 51), the concept of molecular mimicry
provides a framework for explaining the modulation of im-
mune responses to self, both in the development of au-
toimmune disease and in protection from autoimmunity.
A recent report by Zhao et al. demonstrated that a coat
protein of HSV type 1 could be recognized by autoreactive
T cells that target corneal antigens in a murine model of
autoimmune herpes stromal keratitis (52). Mutant HSV
type 1 viruses that lacked this epitope did not induce au-
toimmune disease. Our report reveals that mutant viruses
can block autoimmunity, and this appears to be a novel ob-
servation.
The interaction of the immune system with microbes
may allow the selection of viral subtypes. It is interesting to
speculate that attenuation of the immune response by a
peptide derived from a papilloma viral subtype, containing
an APL-like motif, may be desirable for viral survival. A vi-
rus that can subvert immunity might be selected because it
could survive and persist, instead of being eradicated in the
wake of an autoimmune response. The degeneracy of T
cell recognition of MBPp87–99 has been clearly shown
with combinatorial peptide libraries (53). At least in the
case of T cells specific for MBPp87–99, there may be a del-
icate physiological interplay between self- and microbial
antigens, allowing the modulation of autoimmune disease
and the persistence and survival of mutant microbes. Atten-
uating inflammation in the brain may allow microbes to
survive, sequestered within the central nervous system. It is
remarkable that certain viral subtypes are mutated exactly at
a main TCR contact site, and such mutations may represent
an adaptive response of a virus, which then acts as an APL.
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